Últimas noticias sobre Ocean Biomedical (OTC:OCEA) Bolsa

Ocean Biomedical

Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACLS

AMKR

BHAT

BNAI

FLNC

GNPX

HLIT

LIXT

LSCC

NLSP

OCEA

PRLD

SGRY

SLQT

SLXN

TANH

VSTE

Lattice Semiconductor sorprende con un alza del 14,7% en el premercado. Descubre qué otras acciones están en movimiento.

Acciones de Lattice Semiconductor (LSCC) suben un 15%; 20 acciones que se mueven en el premercado

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

PRFX

QUBT

ZCAR

FedEx sube un 8,7% con resultados sólidos y una nueva estrategia. Descubre otras acciones destacadas en premercado hoy.

Las acciones de FedEx (FDX) suben alrededor de un 9%; 20 acciones que se mueven en premercado

OCEAN BIOMEDICAL INC by Ocean Biomediacal, Inc.

Ocean Biomedical Inc

Ocean Protocol - United States Dollar

Ocean Biomedical Inc Warrants (14/02/2028)

Ocean Park High Income ETF

Ocean Park International ETF

Ocean Power Technologies, Inc. Common Stock

Ocean Power Technologies Inc

OCEAN SPRAY 4 PR by Ocean Spray Cranberries, Inc.

Ocean Spray Cranberries Inc

OCEAN THERMAL ENERGY CORP by Ocean Thermal Energy Corp.

Ocean Thermal Energy Corp

OceanFirst Financial Corp. - Common Stock

OceanFirst Financial Corp

OceanFirst Financial Corp FXDFR PRF PERPETUAL USD 25 Ser A

OceanPal Inc

OceanTech Acquisitions I Corp

OceanTech Acquisitions I Corp Units (1 Ord Class A & 1 War)

OceanTech Acquisitions I Corp Warrants (12/05/2026)

OceanTech Acquisitions I Corp Class A

Oceana Group Ltd

OceanaGold Corp

OCEANAGOLD (PHILIPPINES) by OCEANAGOLD (PHILIPPINES) INC.

OceanaGold Philippines Inc

Oceaneering International, Inc. Common Stock

Oceaneering International Inc

OCEANIA HEALTHCARE LTD by Oceania Healthcare Ltd.

Oceania Healthcare Ltd

OCEANIC IRON ORE CORP NEW by Oceanic Iron Ore Corp.

Oceanic Iron Ore Corp

OCEANIC WIND ENERGY INC. by Oceanic Wind Energy Inc.

Oceanic Wind Energy Inc

Management

Oceaneering International Vice President And CFO Alan R. Curtis To Retire From His Position Effective January 1, 2026.

Offerings

General

SCWO

374water Files Prospectus Relating To Sale Of Up To $100M Shares Of Common Stock From Time To Time

In the current session, the stock is trading at $417.92, after a 0.43% spike. Over the past month, Motorola Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) stock increased by 2.81%, and in the past year, by 11.80%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1749243635_0.png" alt="Past Year Chart" />

<h3>Comparing Motorola Solutions P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 84.77 in the Communications Equipment industry, Motorola Solutions Inc. has a lower P/E ratio of 34.71. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749243635_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

A Look Into Motorola Solutions Inc's Price Over Earnings

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) has outperformed the market over the past 15 years by 5.46% on an annualized basis producing an average annual return of 17.46%. Currently, Prestige Consumer has a market capitalization of $4.20 billion. 
Buying $1000 In PBH: If an investor had bought $1000 of PBH stock 15 years ago, it would be worth $11,018.13 today based on a price of $85.06 for PBH at the time of writing.
<h3>Prestige Consumer's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749243626_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

AMZE

Amaze Holdings To Offer & Sell Up To 44.6M Shares Of Common Stock By Selling Stockholder

WIIM

Nuveen Insured California Premium Fund Ii

NCL stock has given up its prior gain. Northann shares were trading higher amid ongoing volatility. The company announced  that it is not aware of any new material developments or pending announcements concerning its business operations that may be contributing to the recent volatile market activity.

OACC

Oaktree Acquisition Corp. III Life Sciences CFO Courtney Conigliaro Resigned On June 3, 2025;  Thomas Sweeney Named As New Chief Financial Officer Effective Immediately

BBAI

BigBear.ai Names Sean Ricker Interim Chief Financial Officer, Effective Immediately

TIVC

Tivic Health Systems Inc Files For Resale Of 8.4M Shares Of Common Stock By Selling Stockholder

On June 6, 2025, Nektar Therapeutics (the "Company") filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the "Increase in Authorized Shares Amendment") with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company's common stock, par value $0.0001 (the "Common Stock"), from 300,000,000 shares to 390,000,000 shares. The Increase in Authorized Shares Amendment was previously approved by the Company's stockholders at the Annual Meeting of Stockholders held on May 23, 2025 and became effective upon its filing.
&nbsp;
A copy of the Increase in Authorized Shares Amendment is filed as Exhibit 3.1 hereto and is incorporated herein by reference.
&nbsp;
On June 6, 2025, the Company also filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the "Reverse Stock Split Amendment") with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company's Common Stock at a ratio of one-for-fifteen (the "Reverse Stock Split"). The Reverse Stock Split Amendment provides that the Reverse Stock Split will become effective as of 11:59 p.m. Eastern Time on June 8, 2025 (the "Effective Time"), at which time every fifteen shares of the Company's Common Stock issued and outstanding immediately prior to the Effective Time will be automatically combined into one share of Common Stock. No fractional shares of Common Stock will be issued as a result of the Reverse Stock Split. Instead, any fractional shares resulting from the Reverse Stock Split will be rounded up at the participant level with The Depository Trust Company, if such shares of Common Stock are held directly or rounded down to the nearest whole share of Common Stock, if such shares are subject to an award granted under the 2017 Amended and Restated Performance Incentive Plan.
&nbsp;
Trading of the Company's common stock on a split-adjusted basis will begin at market open on June 9, 2025 under the existing symbol "NKTR" and new CUSIP number 640268306. The Reverse Stock Split will not change the number of authorized shares of the Company's Common Stock, which will remain at 390,000,000 shares following effect of the Increase in Authorized Shares Amendment.
&nbsp;
A copy of the Reverse Stock Split Amendment is filed as Exhibit 3.2 hereto and is incorporated herein by reference.

Stock Split

NKTR

Nektar Therapeutics Files Amendments To Increase Authorized Common Stock From 300M To 390M Shares And Implement 1-For-15 Reverse Stock Split Effective June 8, 2025; Split-Adjusted Trading To Begin June 9, 2025

Guidance

PLCE

Children's Place Says Results Remain Under Pressure Due To Current Macroeconomic Environment;For Fiscal 2025, We Expect To See Continued Top-line Sales Pressures

BRZE

Braze Files For Resale Of $3.9M Shares Of Class A Common Stock By Selling Stockholders

NOTE

FiscalNote Holdings Files For Offering Of Up To 12.5M Class A Common Stock By Selling Stockholder

LVWR

Livewire Group Tralisa Maraj Resigns As CFO Effective July 11, 2025

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1190935/000119312525137029/d191650d424b5.htm" title="https://www.sec.gov/ix?doc=/Archives/edgar/data/1190935/000119312525137029/d191650d424b5.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1190935/000119312525137029/d191650d424b5.htm</a>

Pimco Announces $1B Offering

Asbury Automotive Group Expects Herb Chambers Deal To Close By July 2025

IOTR

iOThree Receives Nasdaq Notice For Non-Compliance With $1.00 Bid Price Requirement

The Oncology Institute Files For Stock Shelf Of Up to $50M

CAPT

Captivision Receives Staff Determination Notice From Nasdaq

MOVE

CORRECTION: Movano Announced Its Nasdaq Notification Of Deficiency On May, 23

Press Releases

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.

Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway

Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development

"Cybersecurity, Healthcare Innovators PTPI, SWISF, OCEA, DGLY, LYT, SIGL, Amid FBI Warnings, Signal App Breach, and Data Privacy Crisis"

Sekur Private Data Ltd. (OTCQB: SWISF) (CSE: SKUR): Cybersecurity Platform Redefines Privacy

Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

Ocean Biomedical Expands into Energy and Digital Asset Sectors to Accelerate Growth and Shareholder Value

Comments

Ocean Biomedical

Noticias

Últimas noticias sobre Ocean Biomedical (OTC:OCEA) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL